Oramed Pharmaceuticals Inc. Logo

Oramed Pharmaceuticals Inc.

Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.

ORMP | TA

Overview

Corporate Details

ISIN(s):
US68403P2039
LEI:
Country:
Israel
Address:
20 Mamilla Avenue, 9414904 Jerusalem
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development of oral drug delivery systems. Established in 2006, the company leverages its proprietary platform technology to transform injectable drugs into oral therapies, aiming to enhance patient comfort, compliance, and safety. Its flagship product is an oral insulin capsule for the treatment of type 2 diabetes, which has undergone extensive clinical development. Oramed's primary focus is on providing non-invasive alternatives to injected medications, particularly for chronic conditions like diabetes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-22 09:42
Post-Annual General Meeting Information
Other Report or Announcement
English 118.7 KB
2025-08-22 09:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-22 09:41
Registration Form
Other Report or Announcement
English 181.3 KB
2025-08-22 09:41
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-17 15:18
Foreign Filer Report
FORM 10-Q- FINANCIAL STATEMENTS AS OF JUNE 30, 2025
English 36.4 KB
2025-08-17 15:16
Major Shareholding Notification
Form 13G
English 93.7 KB
2025-08-17 15:16
Foreign Filer Report
Form 13G
English 36.4 KB
2025-07-23 17:53
Delisting Announcement
Option Agreement for the Repurchase of Warrants
English 316.7 KB
2025-07-23 17:53
Foreign Filer Report
Option Agreement for the Repurchase of Warrants
English 36.4 KB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 1.4 MB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 36.4 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 448.1 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 36.4 KB
2025-07-18 14:50
Annual / Quarterly Financial Statement
Other Report or Announcement
English 359.9 KB
2025-07-18 14:50
Foreign Filer Report
Other Report or Announcement
English 36.4 KB

Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oramed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.